LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
1.5 mL (Note: This volume does not allow for repeat testing.)
Red-top tube or gel-barrier tube
Separate serum from cells within one hour of collection. Transfer to a plastic transport tube before shipping. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.
Refrigerate or freeze.
Grossly hemolyzed; bacterial contamination; lipemic specimen; icteric specimen; non-serum specimen types
ANA are commonly found in a variety of autoimmune diseases. Antibody frequency increases with age in apparently healthy people. ANA patterns on HEp-2 slides provide only general clues about particles (chromatin, nucleosomes, and spliceosomes).
The Farr assay is the most specific method of detecting dsDNA autoantibodies. Significant elevations in dsDNA autoantibody concentrations confirm the diagnosis of systemic lupus erythematosus (SLE). Serial studies of elevated values of dsDNA auto antibodies are useful for predicting activity of SLE.
Anti-MPO autoantibodies aid in assessment of certain autoimmune vasculitides such as microscopic polyarteritis, and crescentic glomerulonephritis. PR-3 is the major target antigen of antineutrophil cytoplasmic autoantibodies (ANCA) that give a cytoplasmic (C-ANCA) autoantibodies (ANCA) which give a perinuclear (pANCA) immunofluorescence pattern.
Anti-PR-3 autoantibodies aid in the assessment of certain autoimmune vasculitides such as microscopic polyartheritis and crescentic glomerulonephritis. PR-3 is the major target antigen of antineutrophil cytoplasmic autoantibodies (ANCA) that give a cytoplasmic (C-ANCA) immunofluorescence pattern. Elevated levels of Anti-PR-3 are classically observed in patients with Wegener granulomatosis (WG), particularly with active disease, and less frequently in other forms of necrotizing vasculitis.
ANTI-GBM autoantibodies are recognized as being important in the pathogenesis of the rapidly progressive glomerulonephritis of Goodpasture's syndrome. Measurements of C3 and C4 are used to detect individuals with inborn deficiency of this factor or those with immunologic disease in whom complement is consumed at an increased rate. These include lupus erythematosus, chronic active hepatitis, certain chronic infections, poststreptococcal and membranoproliferative glomerulonephritis, and others.
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
See individual test components.
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf